TX-MOBIL-1/FORZA-MTRSPRT
25.7.2024 23:52:29 CEST | Business Wire | Press release
Today, the Mobil 1 brand, the world's leading synthetic engine oil, announced its expanded collaboration with Forza Motorsport, the best-selling and most-awarded racing video game franchise, in which gamers and race fans around the world will be able to compete against professional motorsports drivers such as racing legend Tony Stewart and recent INDY NXT winner Jamie Chadwick. Beginning July 25, 2024, gamers and motorsports fans will have the unique opportunity to compete against these drivers on Maple Valley, a United States-themed, Mobil 1-branded, in-game track. Additional professional race car drivers will be announced later this year for gamers to compete against in upcoming Legend vs. Leaderboard Rival Events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725776163/en/
Motorsports icons including Tony Stewart and Jamie Chadwick to race gamers in-game and on-track in Legend vs. Leaderboard Rival Events. (Graphic: Business Wire)
The collaboration continues the celebration of the Mobil 1 brand’s 50th anniversary through exclusive branded content, a chance to win incredible prizes, and the opportunity to beat iconic motorsports driver’s timed laps on the 4.81km virtual course. The Forza Motorsport collaboration marks the Mobil 1 brand’s largest campaign in the video game entertainment space and celebrates both the Mobil 1 team’s 50-year legacy and its longstanding passion for racing.
Kicking off the Legend vs. Leaderboard Rival Events is racing legend Tony Stewart, an American motorsports icon. From July 25 to August 7, 2024, gamers will have the chance to try to beat Stewart’s time on the Maple Valley virtual racetrack. Fans can also look forward to exclusive content on Mobil 1 Racing social media channels – part of a Legend vs. Leaderboard Rival Events social media series – showcasing Stewart setting his time to beat while driving a classic 1969 Ford Mustang Boss 302. New celebrity drivers will be featured in the content series throughout the remainder of 2024. Each month, a new legendary driver will take on the Maple Valley track, providing ongoing challenges, new prizes, and additional content for audiences to enjoy.
“We are thrilled to bring this iconic collaboration to life with Forza Motorsport to continue the celebration of the Mobil 1 brand's historic 50th anniversary,” said Laura Bustard, Global Brand Manager, on behalf of the Mobil 1 team. “This collaboration signifies our continued commitment to innovation and excellence in motorsports while also showcasing our passion for racing beyond a physical racetrack but increasingly in the virtual world. We are proud to have created a dynamic and immersive experience for gamers and race fans that allows us to celebrate our legacy, and we cannot wait to see fans share in the excitement by racing against a variety of professional motorsports drivers.”
Later this summer, the next Legends vs. Leaderboard Rivals Event series will take place and feature British racing driver Jamie Chadwick. From August 29 through September 11, 2024, gamers will have the opportunity to race against the rising motorsports star. Chadwick will be racing a 1967 Corvette as she invites the global Forza Motorsport audience to join her in-game for the chance to beat her timed lap.
Forza Motorsport, created by Turn 10 Studios and Xbox Game Studios, continues to be one of the premier racing games by giving players an opportunity to participate in racing events around a variety of both real and fictional tracks – including some of their favorite tracks – available in-game. As the Mobil 1 brand continues to grow within the gaming space and curate incredible experiences for driving enthusiasts, the Forza Motorsport relationship serves as a key milestone to reach new audiences and provide unique virtual automotive experiences – all while sharing its love of driving at a global level.
The Legends vs. Leaderboard Rival Events will kick off on July 25 and run through December 11, 2024 with five different events for gamers and race fans to participate in.
To stay up to date and learn more about this collaboration, visit https://promotions.mobil.com/offers/Mobil1Gaming-forza. Also, stay tuned for driver announcements and exclusive content on @Mobil1Racing on Instagram and X.
About Mobil 1
For 50 years, the Mobil 1 brand has been trusted by drivers to help keep their engines running longer. Our products combine the latest technology and innovation to exceed the toughest standards of vehicle manufacturers and tuning shops—so consumers can get the most out of their time behind the wheel, both on the road and on the track. Turn every day into an adventure with Mobil 1 products, the world’s leading synthetic motor oil brand. Learn more at www.mobil1.us or and follow @Mobil1Racing on Instagram and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725776163/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom